Phase 3 study · Ono Pharmaceutical · NCT07429266
Ono's phase 3 sapablursen study for polycythemia vera
About 250 adults are planned, and each is picked by chance to get sapablursen or a placebo as a shot under the skin. Neither participants nor study doctors know which for 32 weeks, and then both groups can get sapablursen openly, for up to 156 weeks in all.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Ono's phase 3 sapablursen study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your hematologist.
1. Are you 18 or older?
2. Has a hematologist or another doctor diagnosed you with polycythemia vera (PV)?
The listing names the 2022 WHO and International Consensus Classification criteria, and your hematologist can say whether your diagnosis meets them.3. Do you need phlebotomies, blood removal, to keep your PV under control?
The listing says phlebotomy-dependent but does not say how many phlebotomies that means.4. Is your hematocrit (Hct), the share of your blood made up of red blood cells, under 45%?
The listing asks for a hematocrit under 45% at study start, and your hematologist's office can tell you your latest number.5. Does your hematologist order phlebotomies even when your hematocrit is already under 45%?
6. Have you ever been treated for PV with a TMPRSS6 inhibitor such as sapablursen, or with a hepcidin mimetic?
Rusfertide, a study medicine for PV, is described as a hepcidin mimetic on its own ClinicalTrials.gov listing. Your hematologist can tell you whether any past treatment was in these groups.7. Have you had a serious blood clot, heart attack or stroke in the past month?
The listing counts the month back from the day each person is assigned to a group.The study team also checks for these, which are easier to go over with your hematologist:
- A steady regimen at study start for anyone receiving cytoreduction therapy (CRT)
- Adequate organ function and electrolyte levels
- Post-PV myelofibrosis, as defined by the International Working Group for Myeloproliferative Neoplasms Research and Treatment
- A serious or unstable medical condition, or an uncontrolled psychiatric condition, that would get in the way of following the study
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- UC Irvine Health - Chao Family Comprehensive Cancer CenterOrange, California · Recruiting
- Regis Clinical Research LLC.Miami, Florida · Recruiting
- Florida Clinical Trials GroupPlantation, Florida · Recruiting
- Florida Clinical Trials GroupTamarac, Florida · Recruiting
- Central Georgia Cancer CareMacon, Georgia · Recruiting
- The Center for Cancer & Blood DisordersBethesda, Maryland · Recruiting
- The Cancer and Hematology CentersGrand Rapids, Michigan · Recruiting
- Montefiore Medical CenterThe Bronx, New York · Recruiting
- Gabrail Cancer Center ResearchCanton, Ohio · Recruiting
- The James Cancer Hospital and Solove Research Institute at The Ohio State UniversityColumbus, Ohio · Recruiting
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania · Recruiting
- University of Texas M.D. Anderson Cancer CenterHouston, Texas · Recruiting
- Hematology Oncology Associates of FredericksburgFredericksburg, Virginia · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07429266.
Questions people ask about Ono's phase 3 sapablursen study
Is Ono's phase 3 sapablursen study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-10-29. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Ono's phase 3 sapablursen study?
The listing names 13 US sites, in California, Florida, Georgia, Maryland, Michigan, New York and 4 other states. The full list is in the sites section of this page.
Who can join Ono's phase 3 sapablursen study?
About 250 adults are planned, and each is picked by chance to get sapablursen or a placebo as a shot under the skin. The main listed requirements are in the pre-check on this page, starting with: adults 18 and older. Only the study team decides who can join.
How do I contact the Ono's phase 3 sapablursen study team?
The listing names this contact: Clinical Team, 888-724-3274, clinicaltrials@deciphera.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Ono Pharmaceutical. This page restates the public listing in plain words, and nothing here is medical advice; talk with your hematologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07429266, last updated there 2026-10-29. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your hematologist about whether a study is right for you.